- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanomix Inc., a leading electronic detection company commercializing high-value diagnostic and monitoring applications, today announced an exclusive licensing agreement with MysticMD Inc., a provider of proprietary nano-coatings. Per this agreement, MysticMD will provide Nanomix with intellectual property related to the use of nano-ink for glucose test strip technology. This builds upon earlier work between the two organizations to optimize the technology and explore partnering opportunities.
David Macdonald, Nanomix CEO, said, "We are pleased to have partnered with MysticMD, and believe that our collaboration will create better performing glucose test strips at a lower cost."
Heidi Douglas, co-founder and CEO of MysticMD, said, "We are excited to be working with Nanomix, as they are uniquely positioned to make best use of this IP in product development. With Nanomix' expertise in the area of detection devices, we feel confident that this partnership will enable us to bring this technology to market quickly and effectively through broader collaborations with market leaders."
About Nanomix Inc.
Nanomix is a leading electronic detection company launching detection devices based on Sensation™ technology. These scaleable devices use ultra-sensitive carbon nanotube detection elements combined with proprietary chemistries. They can be deployed across high value respiratory and biomarker detection applications where low power consumption, small size, and ultra-sensitivity offer significant performance advantages and enable unprecedented access to critical information. For additional information, please visit www.nano.com.
MysticMD is an advanced materials company developing proprietary coating solutions using hybrid formulations of carbon nanotubes alloyed with traditional materials and other nano particles to solve real world problems. They are developing an intellectual property portfolio focused on dramatically improving their partners' products in key high value, high opportunity commercial applications. For more information, please visit http://www.mysticmd.com .
For more information, please click here
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
Stealth nanocapsules kill Chagas parasites in mouse models June 22nd, 2016
New nanoparticle technology developed to treat aggressive thyroid cancer: Platform designed to deliver nanotherapy effective in preclinical models of metastatic anaplastic thyroid cancer June 21st, 2016
Soft decoupling of organic molecules on metal June 23rd, 2016
New 'ukidama' nanoparticle structure revealed June 14th, 2016
Programmable materials find strength in molecular repetition May 23rd, 2016